CDEX’s ValiMed Unit Selected to Validate Controlled Substance Returns
Rockville, MD – October 13, 2005 – CDEX Inc. (OTCBB: CEXI) announces that its ValiMed Impaired Clinician Solution to validate narcotic returns from an operating room suite has been selected for use by a major academic medical center in the Chicago area. ValiMed provides a simple and effective way to address the Joint Commission on Accreditation of Healthcare Organizations’ standards requiring that all narcotic waste be validated by a pharmacist before disposal.
“The ValiMed system comprises three components: the instrument, a proprietary library of chemical “fingerprints,” and process automation software. The reporting capabilities of the system can help healthcare organizations document compliance with JCAHO standards for controlled substances,” said Malcolm Philips, CDEX’s CEO and Chairman of the Board. “We are excited and honored by the growing number of major medical facilities that are selecting the ValiMed patent pending technology to assist them and we look forward to expanding relationships with each of them in the future.”
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Jim Griffin or Jerry Blair at 301-881-0080 (cdexmanagement@cdex-inc.com).
